


**GENERAL INFORMATIONS**

Custodian	Société Générale
ISIN code (P Share)	LU2022049022
ISIN code (I Share)	LU2022049295
ISIN code (D Share)	LU2022049378
Valuation	Daily
Management fees A Share	2% of Net assets
Management fees I Share	1% of Net assets
Management fees D Share	1% of Net assets
Performance fees (High Water Mark)	12% including tax of the annual perf over 7%
Entry fees	2% maximum
Exit fees (UCITS acquired)	None
NAV (P Share)	<b>245,18 €</b>
NAV (I Share)	<b>249,85 €</b>
NAV (D Share)	<b>\$ 1 096,10</b>
Inception date (P Share)	27 aug 19
Inception date (I Share)	27 aug 19
Inception date (D Share)	8 jun 21
Net assets	<b>43,08 M€</b>

**Performances and statistics on the 31 of august 2021**



1 year values (Quantalys Data)	RJ Funds Smicrocaps
Volatility 1Y	8,35%
Max Drawdown	-5,71%
Bearish Beta	0,34
Sharpe Ratio	5,79

	1M	2021	2020	2019	Inception
P Share	3,4%	<b>27,8%</b>	17,4%	8,9%	<b>63,5%</b>
I Share	3,4%	<b>28,6%</b>	18,6%	9,3%	<b>64,2%</b>
D Share*	3,5%	<b>9,6%</b>			<b>9,6%</b>

\*Launch of the D Share on June 8, 2021

**PORTFOLIO EXTRA-FINANCIAL ANALYSIS**

Grade average E*	6,61/10
Grade average S*	6,66/10
Grade average G*	5,81/10
Portfolio grade overall ESG**	<b>6,42/10</b>

\*\*proportion of the fund's investments for which non-financial data are available and used to complement fundamental analysis.  
\*\*Qualitative scores calculated using the internal ESG analysis model  
Coverage rate: 100%.



Principles for Responsible Investment

Gay-Lussac Gestion is a signatory of the **United Nations Principles for Responsible Investment (UN-PRI)** since 2020.




TASK FORCE ON CLIMATE-RELATED FINANCIAL DISCLOSURES

Gay-Lussac Gestion is a supporter of the **Task Force on Climate-related Financial Disclosures (TCFD)** since 2021.




The **Raymond James Fund Smicrocaps** fund obtained the **label Relance** on the **5/10/2021**.


**COUNTRY BREAKDOWN**



**THE FUND'S WEEKLY AVERAGE ON ↗ AND ↘\***



**INDUSTRY BREAKDOWN**



**INVESTMENT PROCESS**

- Two defensive criteria, **Low Volatility** and **Low Beta** and one performance criterion, **Momentum** to quantitatively filter the investment universe.
- Selection of 3 to 4 major structural and/or cyclical themes by a quarterly Macroeconomic Committee bringing together economists, strategists, fund managers and financial analysts.
- Definition of the investable universe through the selection of stocks in line with the themes selected and validated by the fundamental analysis of the companies.
- Construction and follow-up of the portfolio in risk budget.

**INVESTMENT OBJECTIVE**

- An **annualized performance of more than 7% over an investment horizon of at least 5 years.**
- The investment themes defined by the Macroeconomic Committee determine the selection of stocks in which we invest.

**MANAGEMENT TEAM**

Louis de FELS	Paul EDON
Hugo VOILLAUME	Thibaut MAISSIN
Guillaume BUHOURS	Arthur BERNASCONI

**RISK EXPOSURE**



## Macroeconomic review

August was marked by an outperformance of US equities compared to Europe's: CAC 40 +1,02%, S&P 500 +3,35%, STOXX 600 +2,18%.

In Europe, economic activity proved resilient against the Delta variant. As vaccination remains well on its way, national governments did not have to implement restrictive measures, which benefitted the economic activity. Most European countries continue to benefit from the deployment of recovery plans (750 billion euros in total until 2023). However, inflation is not decelerating. The consumer price index stood at 3% year-on-year in August, above the 2,7% anticipated. The CPI without energy prices stood at 1,7%. Excluding any surprise from the September 9th meeting, the ECB should maintain the rate of its asset buy-backs. The uncertainty regarding the sanitary situation continues to weigh on the European economies. In that sense, the ECB's monetary policy should remain accommodative for a while, whilst being flexible regarding the PEPP.

In the United States, the publication of the PMI composite was worse (55,4) than expected (58,3), confirming the hypothesis of an economic slowdown. As budget aids continue to be reduced and unemployment benefits expire, all eyes are on the budgetary policy. The US Senate came to an agreement on the 1000 billion dollar infrastructure program bill, but the legislative process promises to be a long one, as the House of Representatives has delayed the vote of the 3500 billion dollar program (the vote on the 1000 billion dollar is conditioned by the 3500 billion dollar one), due to a disagreement between Democrats. In terms of monetary policy, Jerome Powell has confirmed, during the Jackson Hole symposium, that tapering would start before the end of the year, but did not set a date. However, no policy rate hike is expected from the FED as Jerome Powell continues to emphasize that inflation remains transitory. In this uncertain environment, the US 10-year rate stayed on the low-side in August, to reach 1,3088% at the end of the month.

### KEY RATIOS

Investment rate (direct lines)	88,13%
Number of lines	50
PER median 2021	22,48
VE/CA median 2021	1,80
VE/EBIT median 2021	18,55

### TOP FIVE POSITIONS

Name	% net asset
DIGITAL VALUE SPA	4,76%
PHARMANUTRA SPA	4,02%
ROBERTET SA	4,00%
GERARD PERRIER ELECTRIC	3,71%
EXCEET GROUP SE	3,62%

### BREAKDOWN BY MARKET CAPS

Name	% Net asset
More than 500M€	34,25%
From 150 to 500M€	48,21%
Less than 150M€	17,55%
Average Capitalisation (M€)	498,45
Median Capitalisation (M€)	410,57

## Management review

This month, we increased our participation in **Medistim ASA**, **Holland Colours NV** and **Foncière Atland**. **Medistim ASA** is a specialist in assisting equipment for vascular surgery. The group has a leading position in the niche market of vascular and cardiovascular bypass operations. Having demonstrated their effectiveness, bypass operations should progressively gain market share over PCI method, which remains the most common operation in cases of heart disease. Following the widespread use of vaccines, we believe that **Medistim ASA** should benefit from the resumption of hospital investment. We strengthened our position in **Holland Colours**, the specialist in the development of solid and liquid dyes and various additives for the colouring of plastics in the food packaging and construction markets. The group has strong positions in niche markets and good geographical diversification. We continued to increase our participation in the German company **Exceet Group**. This company is a holding company that groups together various businesses in Germany that should gradually be sold off. The holding discount seems unjustified in view of the transaction multiples of the various businesses held by the group. On the sell side, we have reduced our positions in **North Media AS** and **Pharmanutra SpA**. The strong stock market performance of both groups has led to an increase in their volatility. The fundamentals of these two groups remain very strong and they are among our strongest holdings.

### MAIN MOVEMENTS OF THE MONTH

Buy	Sell
Medistim ASA	North Media AS
Holland Colours NV	Pharmanutra SpA
Foncière Atland	